ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: 1379
    Differential Effects Of TNF Inhibitors, Anti-IL-6 Receptor Antibody and CTLA4-Ig On Human Monocytes
  • Abstract Number: 565
    Differential Efficacy Of Human Mesenchymal Stem Cells On Disease In Murine Lupus Based On Source Of Origin
  • Abstract Number: 1623
    Differential Methylation Of Interferon-Related Genes Is Associated With Anti-dsDNA Autoantibody Production In Systemic Lupus Erythematosus
  • Abstract Number: 1886
    Differential Methylation Related To Response To Etanercept In Patients With Rheumatoid Arthritis
  • Abstract Number: 1150
    Differential Regulation Of IL-10 and Dusp1 Production By Kinases In The p38 MAPK Pathway
  • Abstract Number: 28
    Differentiation, Activation, and Autoreactivity Of CD11c+ B Cells (ABCs)
  • Abstract Number: 110
    Differing Disease Expression In Latin American Mestizo and Spanish Caucasian Patients With Rheumatoid Arthritis With The Same Access To Healthcare and Antirheumatic Treatment
  • Abstract Number: 213
    Digital Tomosynthesis for Measurement of Bone Erosion in Gout: Comparison With Computed Tomography
  • Abstract Number: 1400
    Dipeptidyl Peptidase IV (DPP-IV, CD26) Levels In Patients With Rheumatoid Arthritis Treated With Biologic Therapies and Correlation With The Activity Of The Disease
  • Abstract Number: 2658
    Dipeptidyl Peptidase-4 Inhibitors In Type 2 Diabetes May Reduce The Risk Of Autoimmune Diseases
  • Abstract Number: 1769
    Direct and Indirect Costs For Patients With Systemic Lupus Erythematosus In National Cohorts In Sweden
  • Abstract Number: 124
    Disability In Fibromyalgia Is Associated With Greater Self-Reported Symptoms and Functional Impairment
  • Abstract Number: 2367
    Discontinuation Of Biological Therapy Due To Adverse Drug Reactions In Rheumatoid Arthritis Patients: 12 Years Follow-Up
  • Abstract Number: 1425
    Discontinuation Of Tumor Necrosis Factor Inhibitors In Rheumatoid Arthritis Patients In Low Disease Activity: Persistent Benefits
  • Abstract Number: 1055
    Discontinuation Rates In Patients With RA Of Triple Disease Modifying Antirheumatic Therapy
  • « Previous Page
  • 1
  • …
  • 51
  • 52
  • 53
  • 54
  • 55
  • …
  • 193
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology